MPSを用いた薬物性肝障害(DILI)予測の改善とフレームワークの紹介

抄録

Drug-induced liver injury (DILI) is a potentially lethal condition that heavily impacts the pharmaceutical industry, causing approximately 21% of drug withdrawals and 13% of clinical trial failures. Conventional preclinical models often miss drug toxicities, which has caused the pharmaceutical industry to waste time and resources. Organ-on-a-Chip technology has the potential to improve success in drug development pipelines, as it can recapitulate organ-level pathophysiology and clinical responses. This presentation will share the findings of the performance assessment of the Emulate Liver-Chip in the context of DILI prediction and introduce new decision-support frameworks.

There is strong evidence that Liver-Chip technology could significantly reduce the incidence of DILI in drug development. As this is a patient safety issue, it is imperative that developers and regulators explore the incorporation of the technology. The frameworks presented enable the integration of the Liver-Chip into various stages of preclinical development in support of safety assessment.